Compare AMPL & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | HCM |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2021 | 2015 |
| Metric | AMPL | HCM |
|---|---|---|
| Price | $17.41 | $14.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $21.27 | $21.14 |
| AVG Volume (30 Days) | ★ 1.9M | 39.3K |
| Earning Date | 11-04-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $343,214,000.00 | N/A |
| Revenue This Year | $21.64 | $14.11 |
| Revenue Next Year | $16.99 | $11.97 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $9.77 |
| 52 Week High | $18.85 | $16.33 |
| Indicator | AMPL | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 58.76 |
| Support Level | $15.62 | $13.00 |
| Resistance Level | $17.84 | $15.55 |
| Average True Range (ATR) | 0.91 | 0.39 |
| MACD | -0.08 | 0.12 |
| Stochastic Oscillator | 54.61 | 78.46 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.